Enter multiple symbols separated by commas

AtheroGenics Heart Drug Study Falls Short of Goal

AtheroGenics said a heart disease drug it is developing with AstraZeneca, did not meet its primary goal in a large, late-stage clinical trial, but that it will continue its development.

AtheroGenic's shares plummeted nearly 60 percent in pre-market trading while AstaZeneca's shares fell.

The aim of the study was to compare the effect of AtheroGenics' AGI-1067 drug to placebo in patients with heart disease on the time to first incidence of a composite of major adverse cardiovascular events such as resuscitated cardiac arrest, heart attacks, stroke, need for coronary revascularization and hospitalization for unstable angina.

AtheroGenics will continue work on the drug, based on positive results in reducing events such as cardiovascular death, heart attack and stroke, as well as improving several key diabetes parameters.

The company said it will review the data to prepare for discussion with the U.S. Food and Drug Administration on how to proceed. AstraZeneca has 45 days to decide whether to continue the collaboration.

Details of the study will be released at American College of Cardiology meeting in New Orleans on Tuesday, March 27.

Shares of AtheroGenics tumbled $4.84, or 57.34 percent, to $3.40 in pre-market electronic trading. AstraZeneca shares dropped 1.8 percent 2,828 pence ($54.95) on the London Stock Exchange.

AstraZeneca has been working to shore up its pipeline after a number of its experimental drugs failed in late-stage clinical trials.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Why women cheat?

    Is cheating bad? Why do women cheat? The founder and CEO of affair website Ashley Madison tells all, including why he has his eye on China.

  • Judge's gavel

    The Financial Industry Regulatory Authority disciplined several financial services firms and individuals in May 2015.

  • Fine wines & finance

    Why you should try something a little different on date night. Bring the romance and champagne, and a calculator too. Every once in a while have a date to talk money and finance, and keep an important part of your relationship on track. Reporter Sharon Epperson talks to a couple who does just that.

U.S. Video

  • Cramer: Here's a sign the market could rally

    Wall Street's been soaking in red, but "Mad Money" host Jim Cramer has one signal to watch for that could point to another run.

  • Burger war maneuvers

    Cramer looks at the number of company's selling burgers and tries to determine the quality names, as well as those to avoid.

  • Cramer: What's driving defense?

    Cramer says that even though President Obama has made it clear the US can no longer be the world's policeman, the country can become the world's arms dealer. Profiting from defense spending.